In an adult male with a confirmed low testosterone level of approximately 11 nmol/L and symptoms such as decreased libido, fatigue, loss of muscle mass, or mood changes, how should testosterone replacement therapy be initiated and monitored?

Management of Low Testosterone (11 nmol/L ≈ 317 ng/dL) in Adult Men

You should initiate testosterone replacement therapy only if this patient has specific sexual symptoms—diminished libido or erectile dysfunction—after confirming the diagnosis with a second morning testosterone measurement and completing a full hypogonadism workup. A single borderline-low testosterone level of 11 nmol/L (≈317 ng/dL) does not automatically warrant treatment, and therapy for nonspecific complaints like fatigue or mood changes is not evidence-based. 1, 2

---

Step 1: Confirm the Diagnosis

• Repeat morning total testosterone (8–10 AM) on a second occasion to confirm persistent hypogonadism, as single measurements are unreliable due to diurnal variation and assay differences. 2, 3
• Biochemical hypogonadism is defined as two separate morning measurements <300 ng/dL (10.4 nmol/L); your patient's value of 11 nmol/L (≈317 ng/dL) sits just above this threshold, placing him in the "gray zone" (231–346 ng/dL). 2
• In this borderline range, measure free testosterone by equilibrium dialysis and sex hormone-binding globulin (SHBG) to detect functional hypogonadism, especially if the patient is obese or has diabetes. 2, 3

---

Step 2: Differentiate Primary from Secondary Hypogonadism

• After confirming low testosterone, measure serum LH and FSH to distinguish testicular failure (elevated LH/FSH) from hypothalamic-pituitary dysfunction (low/normal LH/FSH). 2, 3
• This distinction is critical: secondary hypogonadism can be treated with gonadotropin therapy to preserve fertility, whereas primary hypogonadism requires testosterone replacement, which causes prolonged azoospermia. 2
• If LH and FSH are low or inappropriately normal, measure serum prolactin; if prolactin >1.5× the upper limit of normal, order a pituitary MRI to exclude prolactinoma. 2, 3
• If testosterone <150 ng/dL with LH/FSH <1.5 IU/L, order pituitary MRI immediately even without elevated prolactin, as non-functioning adenomas may be present. 2

---

Step 3: Assess Symptoms—Only Sexual Dysfunction Justifies Treatment

• Testosterone therapy is indicated only for diminished libido and erectile dysfunction; these are the sole symptoms with proven responsiveness to replacement. 1, 2
• Fatigue, low energy, depressed mood, poor concentration, and reduced physical strength show minimal or no improvement even with confirmed hypogonadism (standardized mean difference for energy ≈0.17, for depression ≈−0.19—both clinically insignificant). 1, 2
• The American College of Physicians explicitly recommends against initiating testosterone to improve energy, vitality, physical function, or cognition, as effect sizes are negligible. 1, 2

Common pitfall: Do not prescribe testosterone for nonspecific symptoms like fatigue or mood changes, even if testosterone is low. The evidence shows no meaningful benefit in these domains. 1, 2

---

Step 4: Screen for Reversible Causes (Especially in Borderline Cases)

• Obesity-associated secondary hypogonadism is the most common reversible cause in middle-aged men; excess adipose tissue increases aromatization of testosterone to estradiol, suppressing LH secretion. 2
  • First-line intervention: weight loss through a hypocaloric diet (500–750 kcal/day deficit) and structured exercise (≥150 min/week moderate-intensity aerobic activity plus resistance training 2–3×/week); a 5–10% weight loss can markedly increase endogenous testosterone. 2
• Screen for metabolic syndrome and type 2 diabetes (fasting glucose, HbA1c, lipid profile), as insulin resistance directly impairs testicular testosterone synthesis. 2
• Review medications: chronic opioids, glucocorticoids, and anabolic steroids suppress the hypothalamic-pituitary axis; anticonvulsants, estrogens, and thyroid hormone elevate SHBG. 2
• Measure TSH to exclude hypothyroidism, which can mimic hypogonadal symptoms. 2
• Consider iron studies if hemochromatosis is suspected (a recognized cause of secondary hypogonadism). 2

---

Step 5: Baseline Safety Assessments Before Initiating Therapy

• Hematocrit/hemoglobin: document baseline; hematocrit >54% is an absolute contraindication to starting testosterone. 2, 3
• PSA and digital rectal exam (if age ≥40 years): PSA >4.0 ng/mL requires urologic evaluation and a negative prostate biopsy before therapy. 2, 3
• Fertility assessment: explicitly confirm the patient does not desire future children, as testosterone causes prolonged azoospermia. 2
• Fasting glucose and HbA1c: screen for diabetes. 2

Absolute contraindications to testosterone therapy: 2, 3

• Active desire for fertility preservation (use gonadotropin therapy instead)
• Active or treated male breast cancer
• Prostate cancer
• Hematocrit >54%
• Severe untreated obstructive sleep apnea
• Recent myocardial infarction or stroke (within 3–6 months)
• Severe/decompensated heart failure

---

Step 6: Initiate Testosterone Therapy (If Criteria Are Met)

Formulation Selection

• Transdermal testosterone gel 1.62% (≈40 mg daily) is first-line due to stable serum levels and a lower risk of erythrocytosis (≈15% vs ≈44% with injectables). 2
• Intramuscular testosterone cypionate/enanthate 100–200 mg every 2 weeks is a cost-effective alternative (≈$156/year vs ≈$2,135/year for gel) but carries a higher erythrocytosis risk. 1, 2
• The American College of Physicians suggests considering intramuscular over transdermal when cost is a concern, as clinical effectiveness and harms are similar. 1

Target Testosterone Levels

• Aim for mid-normal serum testosterone concentrations (500–600 ng/dL) during treatment. 2
• For injectable testosterone, measure levels midway between injections (days 5–7 for weekly dosing, days 7–10 for bi-weekly dosing) to avoid misleading peak or trough values. 2

---

Step 7: Monitoring and Follow-Up

Initial Follow-Up (2–3 Months)

• Measure total testosterone (timed midway between injections for injectables), hematocrit, and PSA; evaluate clinical response—particularly improvement in sexual function and libido—and adjust the dose if symptoms persist with suboptimal hormone levels. 2

Ongoing Monitoring (Every 3–6 Months During Year 1, Then Annually)

• Repeat total testosterone, hematocrit, PSA, and perform digital rectal exam at each visit. 2
• Withhold testosterone if hematocrit rises >54%; consider therapeutic phlebotomy in high-risk patients. 2
• Refer to urology if PSA increases >1.0 ng/mL within the first 6 months or >0.4 ng/mL per year thereafter. 2

Reassess at 12 Months

• Discontinue testosterone if there is no improvement in sexual function after 12 months to avoid unnecessary long-term exposure to potential risks without benefit. 1, 2

---

Expected Treatment Outcomes

• Small but statistically significant improvement in sexual function and libido (standardized mean difference ≈0.35). 1, 2
• Little to no effect on physical functioning, energy, vitality, depressive symptoms, or cognition; effect sizes are negligible. 1, 2
• Modest favorable changes in metabolic parameters (insulin resistance, triglycerides, HDL cholesterol) may be observed. 2

---

Critical Pitfalls to Avoid

• Do not diagnose hypogonadism on a single testosterone measurement or on symptoms alone; require two morning values <300 ng/dL plus specific sexual symptoms. 2, 3
• Do not prescribe testosterone for fatigue, low energy, or mood changes, even if testosterone is low; the evidence shows no meaningful benefit. 1, 2
• Do not omit LH/FSH testing after confirming low testosterone; the primary vs. secondary distinction guides therapy and fertility counseling. 2
• Do not initiate testosterone without confirming the patient does not desire fertility, as exogenous testosterone causes prolonged azoospermia. 2
• Do not ignore mild erythrocytosis (hematocrit 50–52%) in elderly or cardiovascular-high-risk patients, as even modest elevations increase thrombotic risk. 2
• Do not continue full-dose testosterone when hematocrit exceeds 54%; this is an absolute indication to withhold therapy. 2

---

Special Considerations

If Fertility Is Desired

• Gonadotropin therapy (hCG + FSH) is mandatory in secondary hypogonadism with fertility concerns; exogenous testosterone is contraindicated. 2
• Combined hCG + FSH therapy restores both serum testosterone and spermatogenesis, providing optimal outcomes for fertility preservation. 2

If Obesity-Associated Hypogonadism

• Attempt weight loss through lifestyle modification before initiating testosterone, as the condition is potentially reversible. 2
• Weight loss of 5–10% can significantly increase endogenous testosterone production in obese men with secondary hypogonadism. 2

Cardiovascular Safety

• The 2023 TRAVERSE trial (5,246 men, ages 45–80 years) showed no significant increase in major adverse cardiac events or stroke with transdermal testosterone gel compared with placebo over 21.7 months, even in men at high cardiovascular risk. 2